UAE Generic Pharmaceuticals Market Size, Share & Forecast, By Product Type, Therapeutic Area & Distribution Channel, 2025–2032

The UAE Generic Pharmaceuticals Market was valued at USD 1,300 million in 2025. The estimate reflects human-use generic medicines supplied for domestic UAE consumption and includes simple generics, specialty generics and biosimilars while excluding originator patented medicines and export revenue. The sizing model combines national pharmaceutical sales, historic generic penetration, manufacturer and importer revenue benchmarks and dispensing-demand indicators. Generic penetration has expanded as healthcare buyers seek lower-cost alternatives, while federal and emirate-level policies increasingly support substitution and domestic pharmaceutical manufacturing.

The market is projected to reach USD 2,242 million by 2032, representing an 8.10% CAGR from 2025 to 2032. Growth is expected to remain above broader mature-market generic growth because UAE penetration continues to benefit from substitution, population growth, chronic-disease treatment and localization. The expansion rate nevertheless moderates from the historical period as conventional oral generics become more established. Incremental value increasingly shifts toward specialty generics, complex formulations and biosimilars, which combine higher technical barriers with significant payer interest in reducing branded medicine expenditure.

Specialty generics, biosimilars and complex formulations represent the strongest profit-pool migration opportunity. Simple generics accounted for approximately 72.3% of category revenue in 2025, but their mix is expected to decline as technically demanding alternatives expand. Biosimilars are especially attractive because they address high-cost biologic therapies while reducing payer expenditure. UAE biosimilar pricing reforms previously produced price declines of approximately 34%, increasing affordability. Manufacturers with sterile production, biologic capabilities, regulatory expertise and differentiated formulations can therefore compete in categories with higher barriers than conventional tablets and capsules.

The primary structural risk is the combination of import dependence and regulated pricing. Domestic pharmaceutical manufacturers represented only 4.4% of domestic pharmaceutical-market sales in 2023, leaving supply chains dependent on imported finished medicines, APIs and international portfolio owners. At the same time, regulated pricing and mandatory generic substitution compress price premiums available to undifferentiated products. Companies therefore face a two-sided challenge: securing resilient supply while maintaining margins. Local manufacturing, multi-source procurement and higher-complexity products can reduce these exposures, but each requires stronger capital, quality and regulatory capabilities.

The UAE ranks second by value within the selected Saudi Arabia, UAE, Qatar, Kuwait and Bahrain peer set. Saudi Arabia remains the largest national generic market because of its substantially larger population and pharmaceutical demand base. The UAE differentiates itself through purchasing power, high digital connectivity, developed private healthcare channels and increasingly coordinated localization policy. Its modeled 8.10% CAGR through 2032 is stronger than the approximately 6.2% trajectory used for Saudi Arabia and 6.9% for Kuwait, supporting a favorable combination of market scale and above-peer growth.

Demand is supported by population expansion, chronic-disease prevalence and a dense pharmacy network. Adult diabetes prevalence stands at 11.8%, with a further 11.7% of adults classified as prediabetic, creating sustained demand for long-duration metabolic therapies. The country also had approximately 4,359 pharmacies in 2023, improving medicine accessibility across retail channels. Generic medicines benefit disproportionately where treatment is recurring because insurers, hospitals and patients have persistent incentives to reduce cumulative therapy costs while maintaining clinically equivalent treatment options.